Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug

Published on 31 Dec 2024 on Bloomberg · via Yahoo Finance

(Bloomberg) -- Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 15 Small-Cap Stocks Poised to Outperform in 2025. In this...

Insider Monkey · via Yahoo Finance 7 Jan 2025

Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutic...

The Business Journals 31 Dec 2024

Pfizer move means Sangamo won’t receive an expected payout in the first quarter, creating a cash...

Market Watch 31 Dec 2024

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market o...

Insider Monkey · via Yahoo Finance 31 Dec 2024

(Bloomberg) -- Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended...

Bloomberg · via Yahoo Finance 31 Dec 2024

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercializatio...

Benzinga · via Yahoo Finance 31 Dec 2024

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their...

Investing.com 31 Dec 2024

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Sangamo...

Zacks · via Yahoo Finance 31 Dec 2024

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are goi...

Insider Monkey · via Yahoo Finance 31 Dec 2024

Upfront License Fees and Milestone Payments: Received $50 million from Genentech. Cash Runway:...

GuruFocus.com · via Yahoo Finance 13 Nov 2024